
Market Assessment
Using the most comprehensive secondary data sources and proven analytics in the industry, our KOL identification solutions help you identify the right leader, for the right role, across the entire product lifecycle.
Formerly known as Activate Networks, our visualization solutions allow communication of complex data integration. These solutions provide the level of precision necessary to achieve the business objectives of identifying both regional and local HCP leaders. This includes data reflecting a physician's expertise (KOL qualifications), as well as clinical behaviors, which enables effective targeting based on customers' current needs.
We have the most comprehensive data sources and proven analytics in the industry
Using the most comprehensive secondary data sources and proven analytics in the industry, our KOL identification solutions help you identify the right leader, for the right role, across the entire product lifecycle.
Providing pinpoint analyses that translate account strategies of ACOS / IDNS into actionable sales targeting activities including how to understand the impact of ACO influence on physician choice and what drive a switch in physician behavior.
Magnifying your brand’s reach and commercial targeting effectiveness with physician network analytics, Activate Network Influencer identifies and rank key action leaders by therapeutic area in each community (the doctors who drive brand decision-making) and link them to colleagues whose brand decisions they influence.
Activate Networks
Magnify your brand’s reach and targeting effectiveness with physician network analytics
One year ago, we welcomed Decision Resources Group (DRG) to the Clarivate portfolio of brands. Today we mark the next step in...
In DRG Blog / Mar, 2021
Digital pharmacies, which provide a faster and easier way to get prescriptions, are implementing new technologies to improve...
In DRG Blog / Feb, 2021
In the United States, as the COVID-19 pandemic shuttered non-essential businesses, millions lost their jobs and with them...
In DRG Blog / Feb, 2021
The approval of Shanghai Henlius Biotech’s HLX01—a biosimilar of rituximab (Roche’s MabThera)—in February 2019 marked...
In DRG Blog / Feb, 2021
From potential shortages of generic drugs to a brand new COVID-19 pipeline, this pandemic is undoubtedly impacting pharmacy...
In DRG Blog / Feb, 2021